Malignant Mesothelioma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

 Malignant mesothelioma is a rare form of cancer arising from the mesothelial cells that line various viscera. It is primarily associated with asbestos exposure and is observed in the pleural lining (malignant pleural mesothelioma). The exact mechanisms by which asbestos exposure leads to the development of malignant mesothelioma are not fully understood but are believed to involve repeated pleural inflammation, interference with cell division, activation of proto-oncogenes, and oxidative stress. The three histological subtypes of mesothelioma are epithelioid, sarcomatoid, and mixed, with the epithelioid subtype associated with a better prognosis. Malignant pleural mesothelioma spreads locally, initially affecting the parietal pleura and then spreading to the visceral pleura, chest wall, diaphragm, or mediastinum. Direct invasion of regional lymph nodes, particularly the bronchopulmonary or hilar nodes, is also observed. The initial symptoms of malignant pleural mesothelioma are usually vague and atypical, including abdominal pain, distension, weight loss, anorexia, and ascites. The differential diagnosis for this condition includes several other lung cancers, benign pleural masses, and lung infections. Multiple factors, including the presentation stage, gender, and the extent of surgical resection, influence the prognosis of malignant pleural mesothelioma. Patients who underwent successful surgical resection have a significantly better prognosis, with longer median survival and higher 5-year survival rates.

·       In the USA, the overall prevalence of malignant mesothelioma is estimated to be 1-2 cases per million annually.

Thelansis’s “Malignant Mesothelioma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Malignant Mesothelioma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Malignant Mesothelioma across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Malignant Mesothelioma Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Malignant Mesothelioma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032